[{"id":"c036a3ed-502a-4c41-8d13-14908c9e503d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05877651","created_at":"2023-05-30T15:07:45.389Z","updated_at":"2024-07-02T16:35:46.951Z","phase":"Phase 1","brief_title":"MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.","source_id_and_acronym":"NCT05877651","lead_sponsor":"SYZ Cell Therapy Co..","biomarkers":" IL10","pipe":"","alterations":" ","tags":["IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MASCT-I"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/21/2020","start_date":" 04/21/2020","primary_txt":" Primary completion: 10/15/2021","primary_completion_date":" 10/15/2021","study_txt":" Completion: 10/15/2021","study_completion_date":" 10/15/2021","last_update_posted":"2023-05-29"}]